Hiroshi Sunaga

Hiroshi Sunaga

Auto-generated profile, based on publicly available information

Hiroshi Sunaga

Department of Anesthesiology, The Jikei University School of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
YMYusuke Miyazaki
Yusuke Miyazaki
HSHiroshi Sunaga
Hiroshi Sunaga
KKKotaro Kida
Kotaro Kida
SHShotaro Hobo
Shotaro Hobo
NINobuyoshi Inoue
Nobuyoshi Inoue
SUShoichi Uezono
Shoichi Uezono
We retrospectively investigated the incidence of potential sugammadex-induced anaphylaxis at a single center in Japan over a period of 3 years. The overall incidence of intraoperative hypersensitivity reaction was 0.22% (95% confidence interval [CI], 0.17%–0.29%), and the incidence of anaphylaxis was 0.059% (95% CI, 0.032%–0.10%). The total number of patients who received sugammadex during the study period was 15,479, and the incidence of anaphylaxis associated with sugammadex was 0.039% (n = 6; 95% CI, 0.014%–0.084%). This result implies that the incidence of sugammadex-associated anaphylaxis could be as high as that for succinylcholine or rocuronium. A prospective study, including testing for identification of cause, is necessary to confirm the exact incidence of sugammadex-induced anaphylaxis; however, the present finding calls attention to this potential.

1 June 2000 in Clinical Immunology
Verified
Journal Article
Closed access
SFShigeharu Fujieda
Shigeharu Fujieda
SSSatoru Suzukib
Satoru Suzukib
HSHiroshi Sunagaa
Hiroshi Sunagaa
HYHideyuki Yamamotoa
Hideyuki Yamamotoa
MSMizue Sekia
Mizue Sekia
HSHitoshi Saito
Hitoshi Saito

18 October 2021 in JA Clinical Reports
Verified
Journal Article
Open access
PDF file
KUKeita Uchiyama
Keita Uchiyama
HSHiroshi Sunaga
Hiroshi Sunaga
NKNobuyuki Katori
Nobuyuki Katori
SUShoichi Uezono
Shoichi Uezono

1 March 2007 in Auris Nasus Larynx
Verified
Journal Article
Closed access
YHYuki Hamajima
Yuki Hamajima
SFSigeharu Fujieda
Sigeharu Fujieda
HSHiroshi Sunaga
Hiroshi Sunaga
TYTakechiyo Yamada
Takechiyo Yamada
KMKazuho Moribe
Kazuho Moribe
SMShingo Murakami
Shingo Murakami

11 February 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KSKaoru Suzuki
Kaoru Suzuki
HSHiroshi Sunaga
Hiroshi Sunaga
KYKentaro Yamakawa
Kentaro Yamakawa
YSYoshifumi Suga
Yoshifumi Suga
IKIchiro Kondo
Ichiro Kondo
SUShoichi Uezono
Shoichi Uezono
Background: Neuromuscular blocking agents induce muscle paralysis via the prevention of synaptic transmission at the neuromuscular junction and may have additional effects at other sites of action. With regard to potential effects of neuromuscular blocking agents on the central nervous system, a definitive view has not been established. We investigated whether intravenous infusion of rocuronium bromide affects the emergence from propofol anesthesia. Methods: Using an in vivo rat model, we performed propofol infusion for 60 minutes, along with rocuronium bromide at various infusion rates or normal saline. Sugammadex or normal saline was injected at the end of the infusion period, and we evaluated the time to emergence from propofol anesthesia. We also examined the neuromuscular blocking, circulatory, and respiratory properties of propofol infusion along with rocuronium bromide infusion to ascertain possible factors affecting emergence. Results: Intravenous infusion of rocuronium bromide dose-dependently increased the time to emergence from propofol anesthesia. Sugammadex administered after propofol infusion not containing rocuronium bromide did not affect the time to emergence. Mean arterial pressure, heart rate, partial pressures of oxygen and carbon dioxide, and pH were not affected by rocuronium bromide infusion. Neuromuscular blockade induced by rocuronium bromide, even at the greatest infusion rate in the emergence experiment, was rapidly antagonized by sugammadex. Conclusions: These results suggest that intravenous infusion of rocuronium bromide dose-dependently delays the emergence from propofol anesthesia in rats. Future studies, such as detection of rocuronium in the cerebrospinal fluid or central nervous system, electrophysiologic studies, microinjection of sugammadex into the brain, etc., are necessary to determine the mechanism of this effect.

1 September 2006 in Anesthesia & Analgesia
Verified
Journal Article
Closed access
HSHiroshi Sunaga
Hiroshi Sunaga
MKMasahisa Kaneko
Masahisa Kaneko
YAYoshikiyo Amaki
Yoshikiyo Amaki
To investigate the suitability of the intratracheal (IT) route as an alternative route for the administration of vecuronium, we compared the pharmacodynamic parameters for neuromuscular block in three groups of rats given vecuronium via the IT, IM, and IV routes. We also examined the pharmacokinetics of vecuronium in the three groups. The doses for the IT, IV, and IM groups were set at 1.50, 0.300, and 2.25 mg/kg, respectively. The onset of action in the IT group (127 +/- 17 s) was significantly earlier than that in the IM group (267 +/- 62 s), and significantly later than that in the IV group (18 +/- 7 s) (P < 0.05 by analysis of variance and the Tukey-Kramer analysis). The duration of action in the IT group (794 +/- 162 s) was significantly longer than that in the IV group (93 +/- 30 s) but not significantly different from that in the IM group (743 +/- 131 s). The recovery index in the IT group (134 +/- 30 s) was significantly shorter than that in the IM group (222 +/- 47 s) and significantly longer than that in the IV group (32 +/- 12 s). Although IT administration of vecuronium is still slower than IV administration, it appears to be more advantageous as compared with IM administration, given the more rapid absorption and faster onset of action.